MedTrace Logo

Polyvinyl Alcohol Embolization Microspheres

NCT05770635 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2023-03-15

No results posted yet for this study

Summary

To evaluate the safety and efficacy of polyvinyl alcohol embolization microspheres developed and manufactured by Shanghai Huihe Medical Technology Co., LTD. (hereinafter referred to as Huihe Medical) for transarterial chemoembolization of primary liver cancer using a prospective, multi-center, randomized controlled method

Conditions

  • Primary Liver Cancer

Interventions

DEVICE

Embosphere and chemotherapy drug

chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition

DEVICE

Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug

chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition

Sponsors & Collaborators

  • Shanghai Huihe Medical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-28
Primary Completion
2024-12-28
Completion
2024-12-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770635 on ClinicalTrials.gov